Skip to content
envelope-open icon

sales@atlantiatrials.com

Brain-Gut-Microbiota Axis: A Novel Target for Drug Development

Share this webinar on your network:

Join our Medical Director, Ted Dinan in this free-to-attend presentation. It is now becoming clear that bacteria might have a beneficial effect on mental health. Such bacteria may influence the capacity to deal with stress, reducing anxiety, perhaps positively impacting on mood, and are now called psychobiotics. Whether they are capable of acting like and in some circumstances, replacing antidepressants remains to be seen.

Duration: 34 mins

Webinar Highlights

A novel paradigm in neuroscience

Traditional approaches to developing pharmacological strategies for psychiatric illnesses are no longer yielding results.  There has been no significant breakthrough in depression since the emergence of the SSRIs. There are marked differences in the gut microbiota between patients with major depression and healthy controls.  Patients with major depression show decreased microbial diversity.

+
0
Watched by
0
Questions answered
Webinar

Speakers

Ted Dinan

Ted Dinan

Top cited scientist in the gut-brain axis, over 400 papers published in neurobiology.


Medical Director
Atlantia Clinical Trials

Sign Up to watch:

Brain-Gut-Microbiota Axis: A Novel Target for Drug Development